Recent Quotes (30 days)

You have no recent quotes
chg | %

Ondine Biomedical Inc  

(Public, LON:OBP)   Watch this stock  
Find more results forOBP
17.75
Aug 24 - Close
LON data delayed by 15 mins - Disclaimer
Currency in GBX unless noted
Range     -
52 week 12.00 - 48.95
Open     -
Vol. 0.00
Mkt cap 1.71M*
P/E     -
Div/yield     -
EPS -0.23*
Shares 96,615.00
Beta     -
Inst. own     -
*GBP

Key stats and ratios

Q2 (Jun '11) 2010
Net profit margin -413.28% -725.88%
Operating margin -452.72% -920.10%
EBITD margin - -865.23%
Return on average assets -216.68% -126.40%
Return on average equity - -418.33%
Carbon Disclosure Rating - -

Address

888-1100 Melville Street
VANCOUVER, BC V6E 4A6
Canada
+1-604-6690555 (Phone)
+1-604-6690533 (Fax)

Website links

External links

Analyst Estimates - BusinessWeek
Options - MarketWatch
Director Dealings - Yahoo Finance
Discussion Group - Google Finance

Description

Ondine Biomedical Inc., formerly Ondine Biopharma Corporation is a Canada-based company. The Company is a biotechnology company engaged in the development and commercialization of anti-infective therapies covering a range of spectrum of bacterial, fungal and viral infections primarily using Photodisinfection technology (PDD) as an alternative to the use of antibiotics. PDD employs laser-based activation of compounds with the potential to treat a range of medical infections. The Company intends to develop additional PDD products for the topical treatment of infectious diseases for use by the medical community. During the year ended December 31, 2010, its products have been sold to Periowave Dental Technologies Inc. (PDT) only. In September of 2010 the Company completed the sale of a majority interest in its then wholly owned subsidiary, Sinuwave Technologies Corporation.